Meeting
2017 ASCO Annual Meeting
Phase 1 study to evaluate safety and efficacy of ipilimumab + nivolumab + external beam radiotherapy in patients with metastatic melanoma.
Authors
Michael Andrew Postow
Memorial Sloan Kettering Cancer Center, New York, NY
Michael Andrew Postow , Susan Jane Knox , Danielle McCabe , Mary J. Macri , Paul Schwarzenberger , Toni Ricciardi , Aileen Ryan , Ralph Rudolph Venhaus , Christopher Andrew Barker
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT02659540
Citation
J Clin Oncol 35, 2017 (suppl; abstr TPS9591)
DOI
10.1200/JCO.2017.35.15_suppl.TPS9591
Abstract #
TPS9591
Poster Bd #
199a
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An indirect treatment comparison (ITC) using patient-level data (PLD).
First Author: Dirk Schadendorf
Poster
2023 ASCO Annual Meeting
Preliminary safety and efficacy results from an open-label, multicenter, phase 1 study of RP2 as a single agent and in combination with nivolumab in a cohort of patients with uveal melanoma.
First Author: Joseph J. Sacco
Poster
2023 ASCO Annual Meeting
A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000.
First Author: Zeynep Eroglu
Poster
2023 ASCO Annual Meeting
Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: An AGEO European Cohort.
First Author: Lorenzo Pilla